Qiagen adds AI-powered IPA Investigator to Ingenuity Pathway Analysis suite

• Qiagen expanded AI-driven bioinformatics tools for research and drug discovery, centered on IPA Investigator for Ingenuity Pathway Analysis.
• IPA Investigator lets scientists query datasets in natural language, then recommends analyses, runs workflows, and surfaces traceable supporting evidence.
• University of Bergen testing found the tool flagged misleading sample comparisons, warned on interpretation risk, then suggested improved experimental design.
• Launch of the QIAGEN Discovery Platform extends AI into automated drug discovery workflows to identify targets, biomarkers, and generate hypotheses.
• Qiagen cited the AI bioinformatics market rising to more than $25 billion by 2031 from about $12 billion in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qiagen NV published the original content used to generate this news brief via Business Wire (Ref. ID: 20261006274304) on October 06, 2026, and is solely responsible for the information contained therein.